Drug Trial Radar · NCT06308926
MRG-001 as an Immunoregulatory and Regenerative Therapy for ARDS Patients
Last checked: Nov 20, 2026Latest source record: Aug 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
60
Planned (sponsor's estimate)
Start
Dec 1, 2024
Primary completion
Feb 1, 2026
Study completion Jul 1, 2026
Sponsor
- Lead sponsor
- MedRegen LLCIndustry
- Sponsor type
- Industry
- Collaborators
- Vanderbilt University Medical Center
- First posted
- Mar 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase IIa, dose-ranging, proof-of-concept study of MRG-001 in patients with ARDS. The aim is to determine the safety and preliminary efficacy of MRG-001 across two dose ranges.
Conditions
- Acute Respiratory Distress Syndrome
- Respiratory Failure
- Respiratory Distress Syndrome
- Respiratory Tract Diseases
- Cytokine Storm
Interventions
MRG-001 (Low-dose)Drug
MRG-001 is subcutaneously administered.
MRG-001 (High-dose)Drug
MRG-001 is subcutaneously administered.
PlaceboOther
Saline placebo will be administered subcutaneously based on bodyweight and similar dose as the treatment group.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Hemopoietic stem cell mobilizationTime frame: 24 Hours
- Organ FailureTime frame: 28 Days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.